A pilot study of camrelizumab with docetaxel and cisplatin for the first line treatment in recurrent/metastatic oral squamous cell carcinoma

A pilot study of camrelizumab with docetaxel and cisplatin for the first line treatment in recurrent/metastatic oral squamous cell carcinoma

Abstract Pembrolizumab with cisplatin and 5‐fluorouracil showed survival benefit but relatively high occurrence of treatment‐related adverse events (TRAEs) for recurrent/metastatic oral squamous cell carcinoma (R/M OSCC). A more tolerable regime is needed. This trial enrolled 20 R/M OSCC patients wi...

Full description

Bibliographic Details
Main Authors: Houyu Ju, Dongliang Wei, Yunteng Wu, Yang Liu, Qi Ding, Mengyu Rui, Zongyu Fan, Yanli Yao, Jingzhou Hu, Guoxin Ren
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:MedComm
Subjects:
camrelizumab
first‐line treatment
immunotherapy
oral cancer
Online Access:https://doi.org/10.1002/mco2.312

Internet

https://doi.org/10.1002/mco2.312

Similar Items